The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-02-07

AUTHORS

Yoshimi Ishii, Naoto Tomita, Ukihide Tateishi, Yasufumi Ishiyama, Eri Yamamoto, Yukako Hattori, Maki Hagihara, Etsuko Yamazaki, Yoshiaki Ishigatsubo

ABSTRACT

[18F]fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) is useful for primary staging and evaluation of treatment outcome in diffuse large B cell lymphoma (DLBCL) patients. The reduction in the maximum standardized uptake value (ΔSUVmax) from the initial to the interim 18F-FDG PET scan has been reported to predict survival in DLBCL patients. We retrospectively evaluated ΔSUVmax obtained by PET or PET-computed tomography before and after initial therapy in 31 newly diagnosed DLBCL patients who were treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy. Receiver observation characteristic curve analysis was used to evaluate the optimal cutoff value for the ΔSUVmax for disease progression. The 3-year progression-free survival rate of patients with ΔSUVmax ≥83 and <83 % was found to be 91 and 25 %, respectively (P < 0.001). The 4-year overall survival rate of patients with ΔSUVmax ≥83 and <83 % was found to be 100 and 83 %, respectively (P = 0.046). The ΔSUVmax observed before and after R-CHOP therapy could be useful in the prediction of disease progression and survival in newly diagnosed DLBCL patients. More... »

PAGES

880

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12032-014-0880-0

DOI

http://dx.doi.org/10.1007/s12032-014-0880-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1014433754

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24504845


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Murine-Derived", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorodeoxyglucose F18", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, Large B-Cell, Diffuse", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Positron-Emission Tomography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prednisolone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiopharmaceuticals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rituximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vincristine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishii", 
        "givenName": "Yoshimi", 
        "id": "sg:person.0665120613.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665120613.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tomita", 
        "givenName": "Naoto", 
        "id": "sg:person.01155656464.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155656464.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tateishi", 
        "givenName": "Ukihide", 
        "id": "sg:person.0742073556.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742073556.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishiyama", 
        "givenName": "Yasufumi", 
        "id": "sg:person.01362612150.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362612150.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamamoto", 
        "givenName": "Eri", 
        "id": "sg:person.01342505175.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342505175.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hattori", 
        "givenName": "Yukako", 
        "id": "sg:person.01107773320.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107773320.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hagihara", 
        "givenName": "Maki", 
        "id": "sg:person.0663130331.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663130331.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamazaki", 
        "givenName": "Etsuko", 
        "id": "sg:person.0731243531.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731243531.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishigatsubo", 
        "givenName": "Yoshiaki", 
        "id": "sg:person.01125133646.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125133646.44"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00259-013-2435-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025772213", 
          "https://doi.org/10.1007/s00259-013-2435-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-012-1640-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043703793", 
          "https://doi.org/10.1007/s00277-012-1640-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-012-1602-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016010275", 
          "https://doi.org/10.1007/s00277-012-1602-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-012-2320-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003249840", 
          "https://doi.org/10.1007/s00259-012-2320-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-02-07", 
    "datePublishedReg": "2014-02-07", 
    "description": "Abstract[18F]fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) is useful for primary staging and evaluation of treatment outcome in diffuse large B cell lymphoma (DLBCL) patients. The reduction in the maximum standardized uptake value (\u0394SUVmax) from the initial to the interim 18F-FDG PET scan has been reported to predict survival in DLBCL patients. We retrospectively evaluated \u0394SUVmax obtained by PET or PET-computed tomography before and after initial therapy in 31 newly diagnosed DLBCL patients who were treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy. Receiver observation characteristic curve analysis was used to evaluate the optimal cutoff value for the \u0394SUVmax for disease progression. The 3-year progression-free survival rate of patients with \u0394SUVmax \u226583 and <83\u00a0% was found to be 91 and 25\u00a0%, respectively (P\u00a0<\u00a00.001). The 4-year overall survival rate of patients with \u0394SUVmax \u226583 and <83\u00a0% was found to be 100 and 83\u00a0%, respectively (P\u00a0=\u00a00.046). The \u0394SUVmax observed before and after R-CHOP therapy could be useful in the prediction of disease progression and survival in newly diagnosed DLBCL patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12032-014-0880-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094524", 
        "issn": [
          "1357-0560", 
          "1559-131X"
        ], 
        "name": "Medical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "31"
      }
    ], 
    "keywords": [
      "positron emission tomography", 
      "maximum standardized uptake value", 
      "cell lymphoma patients", 
      "standardized uptake value", 
      "CHOP therapy", 
      "DLBCL patients", 
      "disease progression", 
      "lymphoma patients", 
      "uptake value", 
      "survival rate", 
      "progression-free survival rates", 
      "positron emission tomography scan", 
      "overall survival rate", 
      "emission tomography scan", 
      "optimal cutoff value", 
      "characteristic curve analysis", 
      "initial therapy", 
      "primary staging", 
      "tomography scan", 
      "treatment outcomes", 
      "PET scans", 
      "patients", 
      "cutoff value", 
      "emission tomography", 
      "therapy", 
      "curve analysis", 
      "\u0394SUVmax", 
      "progression", 
      "survival", 
      "tomography", 
      "scans", 
      "diffuse", 
      "staging", 
      "outcomes", 
      "rate", 
      "reduction", 
      "rate of reduction", 
      "evaluation", 
      "values", 
      "initial", 
      "analysis", 
      "prediction", 
      "Receiver observation characteristic curve analysis", 
      "observation characteristic curve analysis"
    ], 
    "name": "The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission tomography scan predicts disease progression in diffuse large B cell lymphoma patients", 
    "pagination": "880", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1014433754"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12032-014-0880-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24504845"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12032-014-0880-0", 
      "https://app.dimensions.ai/details/publication/pub.1014433754"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_626.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12032-014-0880-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12032-014-0880-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12032-014-0880-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12032-014-0880-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12032-014-0880-0'


 

This table displays all metadata directly associated to this object as RDF triples.

276 TRIPLES      22 PREDICATES      98 URIs      86 LITERALS      31 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12032-014-0880-0 schema:about N0642bf94499a4cd2be97084dce9382e1
2 N1b16284811524ea4b28ccf923d1ae885
3 N35d1630cd8324675b2caa9623e0ef89f
4 N37a028856f6e4798996ca948473dce12
5 N4914d52763d74305bd39273c1ab4345d
6 N4fae53dd895748b7afa730514cdef9cf
7 N4fe94955518d4a34a0bbf5e96d296ea9
8 N5d6e404610f14988a3fe938a3ff38039
9 N6115f25e58dd4f17ac1aec7fa3a9fecf
10 N61b7cc8363a449c9b0437732d9f4b948
11 N7a824df4c0f54b12873e815d8356563b
12 N8a81b74ac7f14aaa8176828b509b09d2
13 N98859c1e654f4224a045183036e64c3c
14 Nabcbbd66139243cc8a50800f04b25606
15 Nb33f0e3614c0418491f1e72badc9da40
16 Nc74dae7316a94351b4a2190cea542144
17 Ncdf25a3a49984e5abc60730a9b5ec5fd
18 Nce30111c274f472d904b6c029769816e
19 Nd3972eb5307e48e4a78ebfa85572b013
20 Nd69157d4c0f645f9b19836c2d78bc8ce
21 Nf4d551d7f5ea4211bd90f53fd0ebf330
22 Nf7165040b6714d6a95ac67f00ee1a220
23 Nfe17c90ff7014c20966722ad493423ef
24 Nfef24afa44e64d0f99e5b80f84d8cfef
25 anzsrc-for:11
26 anzsrc-for:1103
27 schema:author N4e704f0dc81d448e88c558604887705c
28 schema:citation sg:pub.10.1007/s00259-012-2320-8
29 sg:pub.10.1007/s00259-013-2435-6
30 sg:pub.10.1007/s00277-012-1602-3
31 sg:pub.10.1007/s00277-012-1640-x
32 schema:datePublished 2014-02-07
33 schema:datePublishedReg 2014-02-07
34 schema:description Abstract[18F]fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) is useful for primary staging and evaluation of treatment outcome in diffuse large B cell lymphoma (DLBCL) patients. The reduction in the maximum standardized uptake value (ΔSUVmax) from the initial to the interim 18F-FDG PET scan has been reported to predict survival in DLBCL patients. We retrospectively evaluated ΔSUVmax obtained by PET or PET-computed tomography before and after initial therapy in 31 newly diagnosed DLBCL patients who were treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy. Receiver observation characteristic curve analysis was used to evaluate the optimal cutoff value for the ΔSUVmax for disease progression. The 3-year progression-free survival rate of patients with ΔSUVmax ≥83 and <83 % was found to be 91 and 25 %, respectively (P < 0.001). The 4-year overall survival rate of patients with ΔSUVmax ≥83 and <83 % was found to be 100 and 83 %, respectively (P = 0.046). The ΔSUVmax observed before and after R-CHOP therapy could be useful in the prediction of disease progression and survival in newly diagnosed DLBCL patients.
35 schema:genre article
36 schema:inLanguage en
37 schema:isAccessibleForFree false
38 schema:isPartOf N1c87f9ae39dd4b1d8e96f2396f93f5b2
39 N7ebc208f49e543b2966cbb9c75fb26bb
40 sg:journal.1094524
41 schema:keywords CHOP therapy
42 DLBCL patients
43 PET scans
44 Receiver observation characteristic curve analysis
45 analysis
46 cell lymphoma patients
47 characteristic curve analysis
48 curve analysis
49 cutoff value
50 diffuse
51 disease progression
52 emission tomography
53 emission tomography scan
54 evaluation
55 initial
56 initial therapy
57 lymphoma patients
58 maximum standardized uptake value
59 observation characteristic curve analysis
60 optimal cutoff value
61 outcomes
62 overall survival rate
63 patients
64 positron emission tomography
65 positron emission tomography scan
66 prediction
67 primary staging
68 progression
69 progression-free survival rates
70 rate
71 rate of reduction
72 reduction
73 scans
74 staging
75 standardized uptake value
76 survival
77 survival rate
78 therapy
79 tomography
80 tomography scan
81 treatment outcomes
82 uptake value
83 values
84 ΔSUVmax
85 schema:name The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission tomography scan predicts disease progression in diffuse large B cell lymphoma patients
86 schema:pagination 880
87 schema:productId N37d68ce905a245539402a35ebd6c0be1
88 N8b02f6e1d4a44496bb947aa7f8879bab
89 Nfe4a6f78ac504729ab05b3f34bc37fdb
90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014433754
91 https://doi.org/10.1007/s12032-014-0880-0
92 schema:sdDatePublished 2022-01-01T18:32
93 schema:sdLicense https://scigraph.springernature.com/explorer/license/
94 schema:sdPublisher Nee61fd1bcddb47648b24b1fc32ff9eb0
95 schema:url https://doi.org/10.1007/s12032-014-0880-0
96 sgo:license sg:explorer/license/
97 sgo:sdDataset articles
98 rdf:type schema:ScholarlyArticle
99 N0642bf94499a4cd2be97084dce9382e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Disease Progression
101 rdf:type schema:DefinedTerm
102 N1b16284811524ea4b28ccf923d1ae885 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Prednisolone
104 rdf:type schema:DefinedTerm
105 N1c87f9ae39dd4b1d8e96f2396f93f5b2 schema:volumeNumber 31
106 rdf:type schema:PublicationVolume
107 N2b457b5e1b884bceadb854eb4d0625dd rdf:first sg:person.0731243531.94
108 rdf:rest Nb63dc488be374ce8ac48902beaae88e3
109 N35d1630cd8324675b2caa9623e0ef89f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Humans
111 rdf:type schema:DefinedTerm
112 N3734a6e7427c4573a4bd23de8198e610 rdf:first sg:person.01107773320.39
113 rdf:rest N476849e30fca48dbbf286a1c623efce2
114 N37a028856f6e4798996ca948473dce12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Fluorodeoxyglucose F18
116 rdf:type schema:DefinedTerm
117 N37d68ce905a245539402a35ebd6c0be1 schema:name doi
118 schema:value 10.1007/s12032-014-0880-0
119 rdf:type schema:PropertyValue
120 N476849e30fca48dbbf286a1c623efce2 rdf:first sg:person.0663130331.38
121 rdf:rest N2b457b5e1b884bceadb854eb4d0625dd
122 N4914d52763d74305bd39273c1ab4345d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Follow-Up Studies
124 rdf:type schema:DefinedTerm
125 N4e704f0dc81d448e88c558604887705c rdf:first sg:person.0665120613.58
126 rdf:rest Ne071c1f3b6944ad4b172f399b1da65b7
127 N4fae53dd895748b7afa730514cdef9cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Aged, 80 and over
129 rdf:type schema:DefinedTerm
130 N4fe94955518d4a34a0bbf5e96d296ea9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Lymphoma, Large B-Cell, Diffuse
132 rdf:type schema:DefinedTerm
133 N5d6e404610f14988a3fe938a3ff38039 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Vincristine
135 rdf:type schema:DefinedTerm
136 N6115f25e58dd4f17ac1aec7fa3a9fecf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Survival Rate
138 rdf:type schema:DefinedTerm
139 N61b7cc8363a449c9b0437732d9f4b948 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Positron-Emission Tomography
141 rdf:type schema:DefinedTerm
142 N7a824df4c0f54b12873e815d8356563b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Antineoplastic Combined Chemotherapy Protocols
144 rdf:type schema:DefinedTerm
145 N7ebc208f49e543b2966cbb9c75fb26bb schema:issueNumber 3
146 rdf:type schema:PublicationIssue
147 N8a81b74ac7f14aaa8176828b509b09d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Middle Aged
149 rdf:type schema:DefinedTerm
150 N8b02f6e1d4a44496bb947aa7f8879bab schema:name dimensions_id
151 schema:value pub.1014433754
152 rdf:type schema:PropertyValue
153 N8b68c3a4d2ae481cae59b1df647484bc rdf:first sg:person.01362612150.73
154 rdf:rest Nd70a6c77a3264ad5bb0cdaabe997ebaf
155 N98859c1e654f4224a045183036e64c3c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Retrospective Studies
157 rdf:type schema:DefinedTerm
158 N9dc71a3fbee24997b47467e200e7c8fd rdf:first sg:person.0742073556.08
159 rdf:rest N8b68c3a4d2ae481cae59b1df647484bc
160 Nabcbbd66139243cc8a50800f04b25606 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Prognosis
162 rdf:type schema:DefinedTerm
163 Nb33f0e3614c0418491f1e72badc9da40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Male
165 rdf:type schema:DefinedTerm
166 Nb63dc488be374ce8ac48902beaae88e3 rdf:first sg:person.01125133646.44
167 rdf:rest rdf:nil
168 Nc74dae7316a94351b4a2190cea542144 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Aged
170 rdf:type schema:DefinedTerm
171 Ncdf25a3a49984e5abc60730a9b5ec5fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Radiopharmaceuticals
173 rdf:type schema:DefinedTerm
174 Nce30111c274f472d904b6c029769816e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Neoplasm Staging
176 rdf:type schema:DefinedTerm
177 Nd3972eb5307e48e4a78ebfa85572b013 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Adult
179 rdf:type schema:DefinedTerm
180 Nd69157d4c0f645f9b19836c2d78bc8ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Female
182 rdf:type schema:DefinedTerm
183 Nd70a6c77a3264ad5bb0cdaabe997ebaf rdf:first sg:person.01342505175.15
184 rdf:rest N3734a6e7427c4573a4bd23de8198e610
185 Ne071c1f3b6944ad4b172f399b1da65b7 rdf:first sg:person.01155656464.01
186 rdf:rest N9dc71a3fbee24997b47467e200e7c8fd
187 Nee61fd1bcddb47648b24b1fc32ff9eb0 schema:name Springer Nature - SN SciGraph project
188 rdf:type schema:Organization
189 Nf4d551d7f5ea4211bd90f53fd0ebf330 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Rituximab
191 rdf:type schema:DefinedTerm
192 Nf7165040b6714d6a95ac67f00ee1a220 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Doxorubicin
194 rdf:type schema:DefinedTerm
195 Nfe17c90ff7014c20966722ad493423ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Cyclophosphamide
197 rdf:type schema:DefinedTerm
198 Nfe4a6f78ac504729ab05b3f34bc37fdb schema:name pubmed_id
199 schema:value 24504845
200 rdf:type schema:PropertyValue
201 Nfef24afa44e64d0f99e5b80f84d8cfef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Antibodies, Monoclonal, Murine-Derived
203 rdf:type schema:DefinedTerm
204 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
205 schema:name Medical and Health Sciences
206 rdf:type schema:DefinedTerm
207 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
208 schema:name Clinical Sciences
209 rdf:type schema:DefinedTerm
210 sg:journal.1094524 schema:issn 1357-0560
211 1559-131X
212 schema:name Medical Oncology
213 schema:publisher Springer Nature
214 rdf:type schema:Periodical
215 sg:person.01107773320.39 schema:affiliation grid-institutes:grid.268441.d
216 schema:familyName Hattori
217 schema:givenName Yukako
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107773320.39
219 rdf:type schema:Person
220 sg:person.01125133646.44 schema:affiliation grid-institutes:grid.268441.d
221 schema:familyName Ishigatsubo
222 schema:givenName Yoshiaki
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125133646.44
224 rdf:type schema:Person
225 sg:person.01155656464.01 schema:affiliation grid-institutes:grid.268441.d
226 schema:familyName Tomita
227 schema:givenName Naoto
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155656464.01
229 rdf:type schema:Person
230 sg:person.01342505175.15 schema:affiliation grid-institutes:grid.268441.d
231 schema:familyName Yamamoto
232 schema:givenName Eri
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342505175.15
234 rdf:type schema:Person
235 sg:person.01362612150.73 schema:affiliation grid-institutes:grid.268441.d
236 schema:familyName Ishiyama
237 schema:givenName Yasufumi
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362612150.73
239 rdf:type schema:Person
240 sg:person.0663130331.38 schema:affiliation grid-institutes:grid.268441.d
241 schema:familyName Hagihara
242 schema:givenName Maki
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663130331.38
244 rdf:type schema:Person
245 sg:person.0665120613.58 schema:affiliation grid-institutes:grid.268441.d
246 schema:familyName Ishii
247 schema:givenName Yoshimi
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665120613.58
249 rdf:type schema:Person
250 sg:person.0731243531.94 schema:affiliation grid-institutes:grid.268441.d
251 schema:familyName Yamazaki
252 schema:givenName Etsuko
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731243531.94
254 rdf:type schema:Person
255 sg:person.0742073556.08 schema:affiliation grid-institutes:grid.268441.d
256 schema:familyName Tateishi
257 schema:givenName Ukihide
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742073556.08
259 rdf:type schema:Person
260 sg:pub.10.1007/s00259-012-2320-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003249840
261 https://doi.org/10.1007/s00259-012-2320-8
262 rdf:type schema:CreativeWork
263 sg:pub.10.1007/s00259-013-2435-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025772213
264 https://doi.org/10.1007/s00259-013-2435-6
265 rdf:type schema:CreativeWork
266 sg:pub.10.1007/s00277-012-1602-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016010275
267 https://doi.org/10.1007/s00277-012-1602-3
268 rdf:type schema:CreativeWork
269 sg:pub.10.1007/s00277-012-1640-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043703793
270 https://doi.org/10.1007/s00277-012-1640-x
271 rdf:type schema:CreativeWork
272 grid-institutes:grid.268441.d schema:alternateName Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan
273 Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
274 schema:name Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan
275 Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
276 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...